Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.

Tiribelli M, Abruzzese E, Capodanno I, Sorà F, Trabacchi E, Iurlo A, Luciano L, Binotto G, Bonifacio M, Annunziata M, Crugnola M, Fanin R.

Ann Hematol. 2019 Sep 16. doi: 10.1007/s00277-019-03802-y. [Epub ahead of print] No abstract available.

PMID:
31529281
2.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

3.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

4.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Haematologica. 2016 Oct;101(10):1200-1207. Epub 2016 Jul 28.

5.

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.

Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, Efficace F, Alimena G.

Support Care Cancer. 2016 Nov;24(11):4487-93. doi: 10.1007/s00520-016-3286-z. Epub 2016 Jun 3.

PMID:
27260015
6.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Haematologica. 2015 Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. Epub 2015 Jun 25.

7.

Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.

Bassi S, Stroppa EM, Moroni CF, Arbasi MC, Trabacchi E, Di Franco A, Lazzaro A, Bernuzzi P, Moretto M, Arcari A, Bosi C, Riva A, Cavanna L, Vallisa D.

Blood Transfus. 2015 Jul;13(3):478-83. doi: 10.2450/2015.0198-14. Epub 2015 Feb 2.

8.

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.

Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D.

Am J Hematol. 2014 Feb;89(2):119-24. doi: 10.1002/ajh.23593.

9.

Inversion time prolongation at late enhancement cardiac MRI in a myeloma patient.

Belloni E, Marchesi G, Aschieri D, Bernuzzi P, Trabacchi E, Vallisa D, Villani GQ, Cavanna L, Michieletti E.

Diagn Interv Radiol. 2012 Nov-Dec;18(6):552-4. doi: 10.4261/1305-3825.DIR.5923-12.2.

10.

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.

Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G.

Haematologica. 2008 Aug;93(8):1252-5. doi: 10.3324/haematol.12642. Epub 2008 Jun 2.

11.

Primary pancreatic lymphoma. A report of five cases.

Arcari A, Anselmi E, Bernuzzi P, Berta R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, Cavanna L.

Haematologica. 2005 Jan;90(1):ECR09. No abstract available.

12.

A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy.

Lazzaro A, Bernuzzi P, Arcari A, Bertè R, Moroni FC, Trabacchi E, Vallisa D, Cavanna L.

Am J Hematol. 2006 Jul;81(7):557. No abstract available.

13.

Presentation of esophageal cancer with solitary splenic metastasis.

Cavanna L, Lazzaro A, Trabacchi E, Anselmi E, Vallisa D, Foroni RP.

Am J Clin Oncol. 2005 Dec;28(6):636-7. No abstract available.

PMID:
16317280
14.

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M.

J Clin Oncol. 2005 Jun 20;23(18):4100-9. Epub 2005 May 2.

PMID:
15867198
15.

Primary pancreatic lymphoma. Report of five cases.

Arcari A, Anselmi E, Bernuzzi P, Bertè R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, Cavanna L.

Haematologica. 2005 Feb;90(2):ECR09.

16.

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.

Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L.

J Clin Oncol. 2005 Jan 20;23(3):468-73.

PMID:
15659492
17.

Primary lung lymphoma.

Vallisa D, Trabacchi E, Cavanna L.

Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):469-71. Review.

PMID:
15584896
18.

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.

Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Blood. 2004 Dec 15;104(13):4245-51. Epub 2004 Aug 19.

PMID:
15319292
19.

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M.

Haematologica. 2004 Feb;89(2):236-7. No abstract available.

20.

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.

Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia.

Blood. 2004 Mar 15;103(6):2284-90. Epub 2003 Nov 26.

PMID:
14645009
21.

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.

Rosti G, Trabacchi E, Bassi S, Bonifazi F, de Vivo A, Martinelli G, Alberti D, Fincato G, Saglio G, Baccarani M; Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Haematologica. 2003 Mar;88(3):256-9.

22.

A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia.

Rosti G, Bonifazi F, Trabacchi E, De Vivo A, Bassi S, Martinelli G, Testoni N, Russo D, Baccarani M.

Leukemia. 2003 Mar;17(3):554-9.

PMID:
12646944
23.

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M; Europena Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group.

Blood. 2001 Nov 15;98(10):3074-81. Review.

PMID:
11698293
24.

Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.

Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini S, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G.

Haematologica. 2001 Mar;86(3):252-9.

25.

Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.

Bonifazi F, De Vivo A, Rosti G, Tiribelli M, Russo D, Trabacchi E, Fiacchini M, Montefusco E, Baccarani M.

Br J Haematol. 2000 Nov;111(2):587-95.

PMID:
11122107
26.

Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)

Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E, de Vivo A, Mianulli A, Trabacchi E, Saglio G, Tura S.

Leukemia. 1999 Oct;13(10):1635-7. No abstract available.

27.

Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures.

Martinelli G, Ottaviani E, Testoni N, Visani G, Terragna C, Amabile M, Trabacchi E, Montefusco V, Tura S.

Bone Marrow Transplant. 1999 Sep;24(6):694-7. No abstract available.

Supplemental Content

Loading ...
Support Center